CoChat

Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; none of the 17 sources its claims cite is checked for support yet.

Abstract

Introduction Thrombotic microangiopathy (TMA) is characterized by the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Complement inhibition with eculizumab is highly efficacious in TMA secondary to complement dysregulation. However, a growing number of eculizumab-nonresponsive TMAs are reported. Recently, a syndromic form of TMA due to recessive variants in RNA exosome components ( EXOSC3 and EXOSC5 ) has been identified. The underlying pathogenesis remains unclear. Methods We identified 34 children across Europe with pontocerebellar hypoplasia 1b (PCH1b) due to EXOSC3 rare variants and reviewed their clinical history for signs of TMA. To further examine the pathogenesis, a tamoxifen-inducible whole-body Exosc3 conditional knockout mouse model ( Exosc3 KO ) was used. Results Thirteen (eight male, five female) cases of EXOSC3-TMA were identified. In the United Kingdom, the incidence of EXOSC3-TMA was 0.004/million/year. Three children received long-term eculizumab therapy: one child failed to respond and two relapsed on treatment. Exosc3 KO demonstrated cell-cycle arrest and apoptosis resulting in death in a median of eight days, with sequelae noted in actively dividing cells in the bone marrow and large intestine. In this timeframe, no kidney pathology was identified. Conclusions EXOSC3-TMA is a severe, early-onset, C5 inhibitor–resistant TMA. EXOSC3-TMA should be considered in eculizumab-resistant pediatric TMA, particularly in the context of neurodevelopmental disease.

Overview

CoChat Summary

TL;DR

Biallelic pathogenic variants in EXOSC3 cause a syndromic form of thrombotic microangiopathy (TMA) in children with pontocerebellar hypoplasia 1b, and this TMA does not respond to terminal complement inhibition with eculizumab. An inducible whole-body Exosc3 knockout mouse shows ribosome-dysfunction sequelae—cell-cycle arrest and apoptosis in rapidly dividing tissues—but does not itself develop kidney TMA.

Key findings

  • TMA was detected in 13 of 34 children (8 male, 5 female) with biallelic EXOSC3 variants; median age at initial TMA presentation was 6 months (range 2–20 months), and all 17 TMA episodes were triggered within 10 days of a preceding infection, most commonly respiratory (n = 11). In the UK, incidence was 0.004/million/year; 10 patients were homozygous and 3 compound heterozygous, and two missense variants accounted for 88% of EXOSC3 alleles in the TMA subgroup (not significantly different from the non-TMA cohort).
  • Clinical outcomes were poor: 11 children with TMA died during follow-up (mean age at death 10 months; range 2–43 months), 8 of 13 had renal function recovery, and 2 required long-term renal replacement. No evidence of complement dysregulation was detected.
  • Eculizumab had no clear role: among 3 children treated with long-term eculizumab, 1 had no response and 2 relapsed on treatment; 2 additional patients received limited doses discontinued because of poor neurologic prognosis.
  • In Exosc3 KO mice, recombination caused rapid weight loss and euthanasia at a median of 8 ± 2 days, with aplastic anemia (mean hemoglobin 89 vs 126 g/l; white blood cells 2.50×10^6 vs 7.18×10^6 cells/ml; platelets 6.12×10^8 vs 1.36×10^9 cells/ml; marrow cells 4.6×10^6 vs 2.5×10^7; reticulocytes 0.45% vs 3.48%), G0/G1 cell-cycle arrest, and increased apoptosis; no renal disease was seen in this period.

Methods

  • Clinical cohort: 34 children with PCH1b and confirmed EXOSC3 rare variants identified through pan-European registries and the UK national aHUS service; clinical history reviewed for TMA, and available samples tested for known genetic and acquired (factor H autoantibodies) causes of complement-mediated atypical HUS.
  • Mouse model: adult (>6 weeks) tamoxifen-inducible whole-body Exosc3 conditional knockout (Exosc3 fl) treated with intraperitoneal tamoxifen; recombination confirmed by GFP flow cytometry; hematology/biochemistry, BrdU cell-cycle flow cytometry, apoptosis flow cytometry, and histology performed.
  • Analysis: clinical characteristics and outcomes described; mouse comparisons used unpaired t tests as reported in figure legends.

Limitations

  • Stated: the Exosc3 KO mouse did not develop TMA; the authors attribute this to differences from human disease, including mouse age, genetic background (complete knockout vs. hypomorphic/missense alleles), and the need for an infectious trigger, and they note that a patient-specific model and/or viral stressor may be required.
  • Stated: adult mice were used to avoid developmental phenotype complications, and complete Exosc3 disruption produced overwhelming cell-cycle arrest/apoptosis in rapidly dividing tissues; all reported EXOSC3 disease involves at least one missense variant with residual exosome function, and constitutive Exosc3 knockout is embryonic lethal.
  • Evident: the human TMA cohort is small (13 affected children), relies on registry/clinical history and available samples, and lacks a patient-specific mechanistic model; the mouse model does not reproduce the kidney TMA phenotype.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.kint.2026.06.028

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (a) Kidney biopsy from EXOSC3-thrombotic microangiopathy (TMA) (patient IX). CD42b (i) and CD61 (ii) immunohistochemistry demonstrating platelet-rich thrombi within arteriole and glomerular capillaries. Martius Scarlet Blue (MSB) highlighting glomerular thrombi and thrombus in arteriole (red-fibrin) with congested glomerular erythrocytes (yellow) (iii). Hematoxylin and eosin demonstrating fi brin-rich thrombi within glomeruli (iv). ( b ) Age at presentation and clinical course. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
Figure 1 (a) Kidney biopsy from EXOSC3-thrombotic microangiopathy (TMA) (patient IX). CD42b (i) and CD61 (ii) immunohistochemistry demonstrating platelet-rich thrombi within arteriole and glomerular capillaries. Martius Scarlet Blue (MSB) highlighting glomerular thrombi and thrombus in arteriole (red-fibrin) with congested glomerular erythrocytes (yellow) (iii). Hematoxylin and eosin demonstrating fi brin-rich thrombi within glomeruli (iv). ( b ) Age at presentation and clinical course. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.CC-BY · From the PDF
Figure 2 (a) Mouse survival after recombination. Exosc3 KO (n = 12) mice demonstrated weight loss, diarrhea, and deterioration in their clinical score, compared with mice with no Cre-recombinase (Cre) expression (n = 13). ( b ) Hematoxylin and eosin (H&E) staining of selected organs in Exosc3 KO × 40 (left) and × 400 (right). (i) Kidney demonstrating normal morphology. (ii) Thymus, showing atrophy with loss of cortical and medullary architecture. (iii) Bone marrow showing decreased cell number. (iv) Large intestine, demonstrating proliferative colitis with eosinophilic material and sloughed cells in the lumen. Results indicating evidence of cell death in rapidly dividing cell types. (c) ( continued ) Hemoglobin (Hb), leucocyte, platelet, reticulocyte count, bone marrow cell count, and blood urea nitrogen levels from mice at
Figure 2 (a) Mouse survival after recombination. Exosc3 KO (n = 12) mice demonstrated weight loss, diarrhea, and deterioration in their clinical score, compared with mice with no Cre-recombinase (Cre) expression (n = 13). ( b ) Hematoxylin and eosin (H&E) staining of selected organs in Exosc3 KO × 40 (left) and × 400 (right). (i) Kidney demonstrating normal morphology. (ii) Thymus, showing atrophy with loss of cortical and medullary architecture. (iii) Bone marrow showing decreased cell number. (iv) Large intestine, demonstrating proliferative colitis with eosinophilic material and sloughed cells in the lumen. Results indicating evidence of cell death in rapidly dividing cell types. (c) ( continued ) Hemoglobin (Hb), leucocyte, platelet, reticulocyte count, bone marrow cell count, and blood urea nitrogen levels from mice atCC-BY · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 14 Not checked · 36 Own results and interpretations

23 more claims

Create a free account to see all 50 claims and to verify the 17 references still open.

See all claims — free account
  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 24 references

Cited by

Still being checked.

Metadata

Authors
Walsh, P. R., Basu, U., Barakat, T. S., Beck, B. B., Bertini, E., Brocklebank, V., Corderio, N., Ćomić, J., Abazi-Emini, N., Fluss, J., George, A., Bülow, M., Gibson, B. G., Hambleton, S., Hoefele, J., Hunt, D., Ivanov, I., Johnson, S., Kotzaeridou, U., Laštůvková, J., Lunn, A., Mallett, G., Pappworth, I., Philippou, H., Platzer, K., Robson, J., Šafka brožková, D., Smith-Jackson, K., Sinha, M. D., Thompson, G., Wood, K., Zanni, G., Prohászka, Z., Laubova, J., Aranka, J., Bojtár, Z., Antal-Konya, V., Bologa, C., Karava, V., Kamilari, T., Georgiadou, E., Tasic, V., Markova, P., Marchbank, K. J., & Kavanagh, D.
Affiliations
  • Newcastle University (GB)
  • Columbia University (US)
  • Erasmus MC (NL)
  • University of Cologne (DE)
  • Bambino Gesù Children's Hospital (IT)
  • NHS Ayrshire and Arran (GB)
  • Institut für Humangenetik (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • Institute of Genetics and Cancer (GB)
  • Medical University Plovdiv (BG)
  • University Hospital Heidelberg (DE)
  • Nottingham University Hospitals NHS Trust (GB)
  • University of Leeds (GB)
  • University Hospital Leipzig (DE)
  • King's College London (GB)
  • Royal Victoria Infirmary (GB)
  • Semmelweis University (HU)
  • Spitalului Clinic de Urgență pentru Copii Maria Sklodowska Curie (RO)
  • National and Kapodistrian University of Athens (GR)
  • Ss. Cyril and Methodius University in Skopje (MK)
Corresponding author
Kavanagh, David
Venue
Kidney International
Publisher
Elsevier BV
Published
2026-10
Volume
110
Issue
4
Pages
1013-1021
ISSN
0085-2538 (ISSN-L)
OpenAlex
W7170035673
Cited by
0
References
24
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Kidney International (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
Funders
  • Kidney Research UK (NU-024193)
  • Wellcome Trust (BH184374)
  • Macular Society
  • Idorsia Pharmaceuticals
  • Medical Research Council
  • Catalyst Biosciences
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
thrombotic microangiopathy, EXOSC3, RNA exosome, complement inhibition, acute kidney injury, conditional knockout mouse model, neurodevelopmental disorders, cell cycle arrest, apoptosis
MeSH terms
Animals, Child, Child, Preschool, Drug Resistance, Europe, Female, Humans, Infant, Kidney, Male, RNA-Binding Proteins, Apoptosis, Mice, Knockout, Complement Inactivating Agents, Mice, Thrombotic Microangiopathies, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney. https://app.cochat.ai/papers/10.1016/j.kint.2026.06.028
The paper
Walsh, P. R., Basu, U., Barakat, T. S., Beck, B. B., Bertini, E., Brocklebank, V., Corderio, N., Ćomić, J., Abazi-Emini, N., Fluss, J., George, A., Bülow, M., Gibson, B. G., Hambleton, S., Hoefele, J., Hunt, D., Ivanov, I., Johnson, S., Kotzaeridou, U., . . . Kavanagh, D. (2026). Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney. Kidney International. https://doi.org/10.1016/j.kint.2026.06.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.